The promise of targeted therapy: Cancer drugs become more specific

Cleveland Clinic Journal of Medicine

Volumn 71, Issue 7, 2004, Pages 551-560

  Segota, Ena ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BORTEZOMIB; CELL SURFACE RECEPTOR; CETUXIMAB; CHLORAMBUCIL; COMPLEMENTARY DNA; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUDARABINE; FOLINIC ACID; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; INTERLEUKIN 2; IRINOTECAN; MONOCLONAL ANTIBODY; MYELOTARG; ONCOPROTEIN; PACLITAXEL; PROTEIN P53; PROTEIN TYROSINE KINASE; RIBOZYME; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; B CELL LEUKEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; BRONCHOSPASM; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INFUSION; DRUG MECHANISM; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FATIGUE; FEVER; FOLLICULITIS; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENE DELIVERY SYSTEM; GENE THERAPY; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFECTION; INTESTINE PERFORATION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PNEUMONIA; RESPIRATORY DISTRESS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; UNITED STATES; URTICARIA; VEIN OCCLUSION; VIRUS REACTIVATION; VOMITING;

EID: 4043180004     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.71.7.551     Document Type: Review

References (31)

1. Bukowski RM. Evolving therapies. Curr Oncol Rep 2002; 4:7-62.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program, J Clin Oncol 1998; 16:2825-2833.
3. Igarashi T, Itoh K, Kobayashi Y, et al. Phase II and pharmacokinetic study of rituximab with eight weekly infusions in relapsed aggressive B-cell non-Hodgkin's lymphoma (B-NHL) [abstract]. Proc Am Soc Clin Oncol 2002; 21:286a.
4. Manero GG, O'Brien S, Cortes J, et al. Update of results of the combination of fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL) [abstract]. Blood 2001; 98:633a.
5. Nieva J, Bethel K, Baker T, et al. Phase II study of rituximab in the treatment of cladribine-failed patients (pts) with hairy cell leukemia (HCL). Blood 2001; 98:364a-365a.
6. Treon SP, Pilarski LM, Belch AR, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25:72-81.
7. Treon SP, Emmanouilides CE, Kimby E, et al. Extended rituximab therapy is highly active and facilitates hematological recovery in patients with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia, WM) [abstract]. Proc Am Soc Clin Oncol 2002; 21:268a (A1068).
8. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002; 16:2092-2095.
9. Delgado J, Bustos JG, Jimenez-Yuste V, et al. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002; 87:113-114.
10. Sievers EL. Efficacy and safety of gemtuzumab ozogamicin in patients with CD-33 positive acute myeloid leukemia in first relapse. Expert Opin Biol Ther 2001; 1:893-901.
11. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2000; 99:3554-3561.
12. Hagberg H, Lundin J, Repp R, et al. Phase II study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides/Sézary syndrome [abstract]. Ann Oncol 2002; 13(suppl 2 ):85.
13. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. Int J Radiat Applications Instrumentation Part B. Nucl Med Biol 1991; 18:389-394.
14. Witzig TE, Gordon LE, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell Non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463.
15. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract]. Proc Am Soc Clin Oncol 2003; 22. Abstract 3646.
16. Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [abstract]. Proc Am Soc Clin Oncol 2003; 22. Abstract 1012.
17. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal-growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19:183-232.
18. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overex-pressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 44:783-792.
20. Gatzemeier U, Groth G, Hirsh V, et al. Gemcitabine/cisplatin alone and with trastuzumab (Herceptin) in patients with non-small cell lung cancer overexpressing HER2: results of a randomised phase II study [abstract]. Proc Am Soc Clin Oncol 2002; 21:297a.
21. Um B, Small EJ, Kivitz S, et al. A phase I/II trial of docetaxel, exstramustine and trastuzumab for the treatment of hormone resistant prostate cancer (HRPC) [abstract]. Proc Am Soc Clin Oncol 2001; 20:172b.
22. Ozcelik C, Erdmann B, Pilz B, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci 2002; 99:8880-8885.
23. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.
24. Kantarijan H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-652.
25. Talpaz M, Silver RT, Druker B, et al. Gleevec (formerly STI571): an active drug in patients with Ph+ chronic myeloid leukemia in accelerated phase-updated results of a phase II study [abstract]. Blood 2001; 98:845a.
26. Demetri GD, Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
27. Fukuoka M, Yano S, Glaccone G, et al. Final results from a Phase II trial of ZD1839 (Iressa) for patients with advanced non-small-cell lung cancer (IDEAL1) [abstract]. Proc Am Soc Clin Oncol 2002; 21:298a.
28. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (Iressa) in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum and docetaxel-based regimens (IDEAL2) [abstract]. Proc Am Soc Clin Oncol 2002; 21:292a.
29. Lynch TJ, Bell DW, Sordella R. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
31. Buchsbaum DJ, Curiel DT. Gene therapy for the treatment of cancer. Cancer Biother Radiopharmacol 2001; 16:275-288.